Resource Center

Go back to Resource Center

Centrum use and progression of age-related cataract in the Age-Related Eye Disease Study: a propensity score approach. AREDS report No. 21.

2006 Aug

Journal Article

Milton, R.C.; Sperduto, R.D.; Clemons, T.E.; Ferris, F.L.







Aged; aging; cataract; Cohort Studies; Disease Progression; Drug Combinations; Female; Humans; Lens, Crystalline; Logistic Models; Male; Photography; Prospective Studies; Treatment Outcome; Vitamins

PURPOSE: To evaluate the effect of the multivitamin Centrum on the development and progression of age-related lens opacities.DESIGN: Clinic-based prospective cohort study.PARTICIPANTS: Four thousand five hundred ninety individuals with at least one natural lens and photographic follow-up (median, 6.3 years) were assessed for development or progression of lens opacities.MAIN OUTCOME MEASURES: Progression of "any" lens opacity or type-specific opacity was ascertained from lens photographs taken at baseline and at annual visits beginning at year 2.METHODS: The Age-Related Eye Disease Study (AREDS) showed no statistically significant effect of a high-dose antioxidant formulation on progression of lens opacities. Centrum also was provided to approximately two thirds of the study participants. Because Centrum use was elective, a logistic regression model of baseline characteristics was used to generate a propensity score for Centrum use. Repeated-measures logistic regression, adjusted for propensity score and other covariates, was used to evaluate associations of Centrum use and lens opacity.RESULTS: Centrum use, adjusted for propensity score and other covariates, was associated with a reduction in "any" lens opacity progression (odds ratio [OR] = 0.84, 95% confidence interval [CI] = 0.72-0.98, P = 0.025). Results for individual lens opacity types suggested that Centrum use was protective for nuclear opacity events (OR = 0.75, 95% CI = 0.61-0.91, P = 0.004).CONCLUSION: Observational data from the AREDS and other studies suggest that use of a multivitamin may delay the progression of lens opacities. A National Eye Institute-sponsored clinical trial scheduled for completion in 2007 will provide additional data on Centrum use and cataract development.

Go back to Resource Center